<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>bcr-2000-66711</ui>
   <ji>BCJ</ji>
   <fm>
      <dochead>Paper Report</dochead>
      <bibl>
         <!-- this bibl is for the report -->
         <title>
            <p>HOXA5 regulation of p53 in breast tumours</p>
         </title>
         <aug>
            <au id="A1">
               <snm>Jones</snm>
               <fnm>Chris</fnm>
               <insr iid="I1"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Royal Free and University College Hospitals, London</p>
            </ins>
         </insg>
         <source>
        Breast Cancer Res
      </source>
         <issn>1465-5411</issn>
         <pubdate>2000</pubdate>
         <volume>3</volume>
         <fpage>66711</fpage>
         <url>http://breast-cancer-research.com/paperreport/bcr-2000-66711</url>
         <xrefbib>
            <pubid idtype="doi">10.1186/bcr-2000-66711</pubid>
         </xrefbib>
         <bibl>
            <!-- this bibl is for the orignal article -->
            <title>
               <p>Compromised HOXA5 function can limit p53 expression in human breast tumours</p>
            </title>
            <aug>
               <au id="A2">
                  <snm>Raman</snm>
                  <fnm>V</fnm>
               </au>
               <au id="A3">
                  <snm>Martensen</snm>
                  <fnm>SA</fnm>
               </au>
               <au id="A4">
                  <snm>Relsman</snm>
                  <fnm>D</fnm>
               </au>
               <au id="A5">
                  <snm>Evron</snm>
                  <fnm>E</fnm>
               </au>
               <au id="A6">
                  <snm>Odenwald</snm>
                  <fnm>WF</fnm>
               </au>
               <au id="A7">
                  <snm>Jaffee</snm>
                  <fnm>E</fnm>
               </au>
               <au id="A8">
                  <snm>Marks</snm>
                  <fnm>J</fnm>
               </au>
               <au id="A9">
                  <snm>Sukumar</snm>
                  <fnm>S</fnm>
               </au>
            </aug>
            <source>Nature</source>
            <issn/>
            <pubdate>2000</pubdate>
            <volume>408</volume>
            <fpage>974</fpage>
            <lpage>978</lpage>
         </bibl>
      </bibl>
      <history>
         <pub>
            <date>
               <day>10</day>
               <month>7</month>
               <year>2000</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2000</year>
         <collab>Current Science Ltd</collab>
      </cpyrt>
      <kwdg>
         <kwd>Breast cancer</kwd>
         <kwd>HOX genes</kwd>
         <kwd>p53</kwd>
         <kwd>transcriptional regulation</kwd>
      </kwdg>
   </fm>
   <meta>
      <classifications>
         <classification type="BMC" subtype="rating">* Of importance</classification>
         <classification type="BMC" subtype="man_spc_id" id="30030006">Molecular genetics</classification>
         <classification type="BMC" subtype="man_spc_id" id="30030009">Pathogenesis and molecular biology</classification>
         <classification type="BMC" subtype="man_spc_id" id="30030008">Pathogenesis and cell biology</classification>
      </classifications>
   </meta>
   <bdy>
      <sec>
         <st>
            <p>Introduction</p>
         </st>
         <p>Mutational inactivation of p53 occurs in only around 20% of human breast cancers, suggesting 
other mechanisms for loss of p53 function in these tumours. Although much work has been 
performed on the control of p53 degradation, information is lacking regarding factors which regulate 
p53 synthesis.
Class I homeobox (<it>HOX</it>) genes are a family of regulatory genes encoding transcription 
factors that primarily play a crucial role during development. Several indications suggest their 
involvement in the control of cell growth and, when dysregulated, oncogenesis.</p>
      </sec>
      <sec>
         <st>
            <p>Aims</p>
         </st>
         <p>To identify and investigate potential regulators of <it>p53</it> transcription.
</p>
      </sec>
      <sec>
         <st>
            <p>Comments</p>
         </st>
         <p>Mutations in the p53 gene which inactivate its cell cycle checkpoint functions have been observed 
in over 50% of all human tumours. In up to 80% of sporadic breast cancers, however, no p53 mutations are found. This important paper indicates that the homeobox gene product HOXA5 may be a 
positive regulator of p53 transcription and function, and that loss of <it>HOXA5</it> expression by 
methylation of the promoter region (resulting in loss of p53 expression) may be a critical step in 
breast tumorigenesis. </p>
      </sec>
      <sec>
         <st>
            <p>Methods</p>
         </st>
         <p>p53 mRNA levels were found to be 5- to 10-fold lower in tumour cells than in normal breast 
epithelium. Six putative HOX-core binding sequences were identified within the 
human <it>p53</it> promoter, and HOXA5 mRNA levels were markedly reduced in breast cancer 
cells. There was a tight correlation of HOXA5 with p53 mRNA levels in 10 cell lines tested for both genes. 
Transient transfection with HOXA5 activated the <it>p53</it> promoter in ZR75.1 breast cancer cells. 
Expression of <it>HOXA5</it> in epithelial cancer cells expressing wild-type p53, but not in isogenic 
variants lacking the <it>p53</it> gene, led to apoptotic cell death. Concurrent loss of p53 and HOXA5 
protein expression was observed in 20 out of 30 primary breast tumours, although HOXA5 mutations 
were absent. The <it>HOXA5</it> promoter region was found to be methylated by methylationspecific PCR of sodium-bisulphite-treated DNA in 16 out of 20 p53-negative 
breast tumour specimens, but not normal human mammary epithelial cells, with strong 
correlations between methylation and gene silencing in these tumours.</p>
      </sec>
      <sec>
         <st>
            <p>Discussion</p>
         </st>
         <p>p53 and HOXA5 mRNA levels were found to be markedly reduced in breast cancer cells, with 
HOXA5  seemingly activating p53 expression. An increase in HOXA5 levels in breast cancer cells 
appeared to increase p53 levels, which in turn resulted in apoptosis. Primary breast tumour 
samples showed concomitant loss of HOXA5 and p53 protein levels, and preliminary evidence 
suggests that methylation of the <it>HOXA5</it> promoter region may be responsible for silencing of 
gene expression. </p>
      </sec>
   </bdy>
   <bm/>
</art>
